---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-22-000034"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:00:34.106713+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024

## Summary
- Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.
- Cash, equivalents & investments $144.2M at Sep 30, 2022, vs $209.8M Dec 31, 2021.
- Net cash used in operations $16.5M for Q3 vs $26.5M a year ago; runway through Q3 2024.
- BDTX-1535 clinical update expected in 2023; IND for BDTX-4933 planned H1 2023.
- Appointed Melanie Morrison as SVP Development Operations in October 2022.

## SEC filing metadata
- accession: 0001701541-22-000034
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/0001701541-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/bdtx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-22-000034
- JSON: https://secwatch.observer/filing/0001701541-22-000034.json
- Plain text: https://secwatch.observer/filing/0001701541-22-000034.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/0001701541-22-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.